相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- Genesis MedTech Group and the National University Health System have established a strategic partnership to advance artificial intelligence in surgery and medical device innovation through a two-phase, four-year program. - The collaboration will co-innovate AI projects in surgery, engage NUHS clinicians for stronger alignment between product development and clinical needs, and establish the "Genesis-NUHS AI Innovation and Surgical Training Lab." - The partnership adopts a design-led approach to translate unmet clinical needs into meaningful solutions, aiming to make surgery safer, smarter and more accessible to patients worldwide. - AI-driven technologies are enabling surgeons with data-driven insights to deliver safer, personalized outcomes while supporting hospitals in providing more cost-effective care.
- Singapore has launched Phase III of its National Precision Medicine programme, aiming to enroll 400,000-450,000 patients from healthcare settings over the next five years to study genomic information in real-world clinical care. - The programme will transition from studying healthy populations to working with patients receiving medical treatment, enabling researchers to understand how genetic, lifestyle and environmental factors interact in clinical settings. - The Ministry of Health is providing financial support for genetic tests, with familial hypercholesterolemia testing costing less than $100 out-of-pocket after subsidies, and has extended insurance protection to prevent genetic discrimination. - Upon completion, over 500,000 participants representing 10% of Singapore's resident population will have undergone whole genome sequencing, positioning the nation as a leader in Asian precision medicine research.
- Standard BioTools' SomaScan 11K Assay was selected by Singapore's PRECISE-SG100K initiative to analyze 100,000 plasma samples in one of the world's largest population health research studies. - The collaboration aims to transform precision medicine by discovering novel genetic associations and biomarkers through comprehensive proteomics analysis of Singapore's multi-ethnic population. - This partnership reinforces SomaScan's leadership in population proteomics, with the platform now being used in more than 30 biobank studies worldwide totaling nearly 160,000 samples this year alone.
- A novel CD7 CAR-T cell therapy developed by NUHS has shown significant promise in treating relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). - In a study of 17 patients, 16 achieved complete remission within one month, demonstrating the therapy's high efficacy in a heavily pre-treated population. - The therapy reprograms patients' own T cells to target CD7-expressing leukemia cells, offering a new curative option without severe side effects. - The first patient treated has remained in remission for five years, suggesting long-term efficacy and potential for a durable cure.
